ABSTRACT
Vizantin, 6,6'-bis-O-(3-nonyldodecanoyl)-α,α'-trehalose, has been developed as a safe immunostimulator on the basis of a structure-activity relationship study with trehalose 6,6'-dicorynomycolate. Our recent study indicated that vizantin acts as an effective Toll-like receptor-4 (TLR4) partial agonist to reduce the lethality of an immune shock caused by lipopolysaccharide (LPS). However, because vizantin has low solubility in water, the aqueous solution used in in vivo assay systems settles out in tens of minutes. Here, vizantin was chemically modified in an attempt to facilitate the preparation of an aqueous solution of the drug. This paper describes the concise synthesis of a water-soluble vizantin analogue in which all the hydroxyl groups of the sugar unit were replaced by sulfates. The vizantin derivative displayed micelle-forming ability in water and potent TLR-4 partial agonist activity.
Subject(s)
Glycolipids , Lipopolysaccharides , Trehalose/analogs & derivatives , Lipopolysaccharides/pharmacologyABSTRACT
Lipopolysaccharide (LPS), an endotoxin, induces systemic inflammation by injection and is thought to be a causative agent of chronic inflammatory diseases, including type 2 diabetes mellitus (T2DM). However, our previous studies found that oral LPS administration does not exacerbate T2DM conditions in KK/Ay mice, which is the opposite of the response from LPS injection. Therefore, this study aims to confirm that oral LPS administration does not aggravate T2DM and to investigate the possible mechanisms. In this study, KK/Ay mice with T2DM were orally administered LPS (1 mg/kg BW/day) for 8 weeks, and blood glucose parameters before and after oral administration were compared. Abnormal glucose tolerance, insulin resistance progression, and progression of T2DM symptoms were suppressed by oral LPS administration. Furthermore, the expressions of factors involved in insulin signaling, such as insulin receptor, insulin receptor substrate 1, thymoma viral proto-oncogene, and glucose transporter type 4, were upregulated in the adipose tissues of KK/Ay mice, where this effect was observed. For the first time, oral LPS administration induces the expression of adiponectin in adipose tissues, which is involved in the increased expression of these molecules. Briefly, oral LPS administration may prevent T2DM by inducing an increase in the expressions of insulin signaling-related factors based on adiponectin production in adipose tissues.
Subject(s)
Diabetes Mellitus, Experimental , Diabetes Mellitus, Type 2 , Lipopolysaccharides , Animals , Mice , Adiponectin/metabolism , Administration, Oral , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/therapy , Insulin/metabolism , Insulin Resistance/physiology , Lipopolysaccharides/administration & dosage , Lipopolysaccharides/pharmacology , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/therapyABSTRACT
BACKGROUND: Sulfated vizantin, a recently developed immunostimulant, has also been found to exert antibiofilm properties. It acts not as a bactericide, but as a detachment-promoting agent by reducing the biofilm structural stability. This study aimed to investigate the mechanism underlying this activity and its species specificity using two distinct ex vivo oral biofilm models derived from human saliva. RESULTS: The biofilm, composed mainly of the genus Streptococcus and containing 50 µM of sulfated vizantin, detached significantly from its basal surface with rotation at 500 rpm for only 15 s, even when 0.2% sucrose was supplied. Expression analyses for genes associated with biofilm formation and bacterial adhesion following identification of the Streptococcus species, revealed that a variety of Streptococcus species in a cariogenic biofilm showed downregulation of genes encoding glucosyltransferases involved in the biosynthesis of water-soluble glucan. The expression of some genes encoding surface proteins was also downregulated. Of the two quorum sensing systems involved in the genus Streptococcus, the expression of luxS in three species, Streptococcus oralis, Streptococcus gordonii, and Streptococcus mutans, was significantly downregulated in the presence of 50 µM sulfated vizantin. Biofilm detachment may be facilitated by the reduced structural stability due to these modulations. As a non-specific reaction, 50 µM sulfated vizantin decreased cell surface hydrophobicity by binding to the cell surface, resulting in reduced bacterial adherence. CONCLUSION: Sulfated vizantin may be a candidate for a new antibiofilm strategy targeting the biofilm matrix while preserving the resident microflora.
Subject(s)
Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Glycolipids/pharmacology , Streptococcus/physiology , Trehalose/analogs & derivatives , Anti-Bacterial Agents/chemistry , Bacterial Adhesion/drug effects , Bacterial Adhesion/genetics , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Biofilms/growth & development , Dental Caries/microbiology , Epithelial Cells/drug effects , Gene Expression/drug effects , Gingivitis/microbiology , Glucosyltransferases/genetics , Glucosyltransferases/metabolism , Glycolipids/chemistry , Humans , Quorum Sensing/drug effects , Quorum Sensing/genetics , Streptococcus/classification , Streptococcus/drug effects , Streptococcus/growth & development , Sulfates/chemistry , Trehalose/chemistry , Trehalose/pharmacologyABSTRACT
Streptococcus mutans is the main pathogen of dental caries and adheres to the tooth surface via soluble and insoluble glucans produced by the bacterial glucosyltransferase enzyme. Thus, the S. mutans glucosyltransferase is an important virulence factor for this cariogenic bacterium. Sulfated vizantin effectively inhibits biofilm formation by S. mutans without affecting its growth. In this study, less S. mutans biofilm formation occurred on hydroxyapatite discs coated with sulfated vizantin than on noncoated discs. Sulfated vizantin showed no cytotoxicity against the human gingival cell line Ca9-22. Sulfated vizantin dose-dependently inhibited the extracellular release of cell-free glucosyltransferase from S. mutans and enhanced the accumulation of cell-associated glucosyltransferase, compared with that observed with untreated bacteria. Sulfated vizantin disrupted the localization balance between cell-associated glucosyltransferase and cell-free glucosyltransferase, resulting in inhibited biofilm maturation. These results indicate that sulfated vizantin can potentially serve as a novel agent for preventing dental caries.
Subject(s)
Biofilms/drug effects , Biofilms/growth & development , Glycolipids/pharmacology , Streptococcus mutans/drug effects , Streptococcus mutans/growth & development , Trehalose/analogs & derivatives , Anti-Bacterial Agents/pharmacology , Bacterial Adhesion/drug effects , Bacterial Proteins/metabolism , Cell Line , Dental Caries/microbiology , Dental Caries/prevention & control , Glucosyltransferases/antagonists & inhibitors , Glucosyltransferases/metabolism , Humans , Sulfates/chemistry , Trehalose/pharmacology , Virulence Factors/metabolismABSTRACT
Bacillus cereus is well known as a causative agent of food poisoning but it also causes bacteremia and endophthalmitis in nosocomial infections. However, as an environmental bacterium that lives in soil, it is often treated as simple contamination by hospitals. In recent years, highly pathogenic B. cereus strains that are similar to Bacillus anthracis have been detected in hospitals. The B. cereus sphingomyelinase contributes to its pathogenicity, as do sphingomyelinases produced by Staphylococcus aureus, Pseudomonas aeruginosa, Helicobacter pylori, and B. anthracis. Highly pathogenic B. cereus produces a large amount of sphingomyelinase. In this review, we describe the regulation of sphingomyelinase expression through the PlcR-PapR system, the pathogenicity of bacterial sphingomyelinases, and their potential as therapeutic drug targets.
Subject(s)
Bacillus cereus/metabolism , Bacillus cereus/pathogenicity , Sphingomyelin Phosphodiesterase/metabolism , HumansABSTRACT
Side-chain derivatives of eurotiumide A, a dihydroisochroman-type natural product, have been synthesized and their antimicrobial activities described. Sixteen derivatives were synthesized from a key intermediate of the total synthesis of eurotiumide A, and their antimicrobial activities against two Gram-positive bacteria, methicillin-susceptible and methicillin-resistant Staphylococcus aureus (MSSA and MRSA), and a Gram-negative bacterium, Porphyromonas gingivalis, were evaluated. The results showed that derivatives having an iodine atom on their aromatic ring instead of the prenyl moiety displayed better antimicrobial activity than eurotiumide A against MSSA and P. gingivalis. Moreover, we discovered that a derivative with an isopentyl side chain, which is a hydrogenated product of eurotiumide A, is the strongest antimicrobial agent against all three strains, including MRSA.
Subject(s)
Anti-Bacterial Agents/pharmacology , Chromans/pharmacology , Porphyromonas gingivalis/drug effects , Staphylococcus aureus/drug effects , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Chromans/chemical synthesis , Chromans/chemistry , Methicillin-Resistant Staphylococcus aureus/drug effects , Structure-Activity RelationshipABSTRACT
Streptococcus pneumoniae is a leading cause of community-acquired pneumonia. Over the past 2 decades, macrolide resistance among S. pneumoniae organisms has been increasing steadily and has escalated at an alarming rate worldwide. However, the use of macrolides in the treatment of community-acquired pneumonia has been reported to be effective regardless of the antibiotic susceptibility of the causative pneumococci. Although previous studies suggested that sub-MICs of macrolides inhibit the production of the pneumococcal pore-forming toxin pneumolysin by macrolide-resistant S. pneumoniae (MRSP), the underlying mechanisms of the inhibitory effect have not been fully elucidated. Here, we show that the release of pneumococcal autolysin, which promotes cell lysis and the release of pneumolysin, was inhibited by treatment with azithromycin and erythromycin, whereas replenishing with recombinant autolysin restored the release of pneumolysin from MRSP. Additionally, macrolides significantly downregulated ply transcription followed by a slight decrease of the intracellular pneumolysin level. These findings suggest the mechanisms involved in the inhibition of pneumolysin in MRSP, which may provide an additional explanation for the benefits of macrolides on the outcome of treatment for pneumococcal diseases.
Subject(s)
Drug Resistance, Bacterial/drug effects , Macrolides/pharmacology , N-Acetylmuramoyl-L-alanine Amidase/metabolism , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/metabolism , Streptolysins/metabolism , Anti-Bacterial Agents/pharmacology , Azithromycin/pharmacology , Bacterial Proteins/metabolism , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Humans , Microbial Sensitivity Tests/methods , Pneumococcal Infections/drug therapy , Pneumococcal Infections/microbiologyABSTRACT
Streptococcus pneumoniae is a leading cause of bacterial pneumonia. Our previous study suggested that S. pneumoniae autolysis-dependently releases intracellular pneumolysin, which subsequently leads to lung injury. In this study, we hypothesized that pneumococcal autolysis induces the leakage of additional intracellular molecules that could increase the pathogenicity of S. pneumoniae. Liquid chromatography tandem-mass spectrometry analysis identified that chaperone protein DnaK, elongation factor Tu (EF-Tu), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were released with pneumococcal DNA by autolysis. We demonstrated that recombinant (r) DnaK, rEF-Tu, and rGAPDH induced significantly higher levels of interleukin-6 and tumor necrosis factor production in peritoneal macrophages and THP-1-derived macrophage-like cells via toll-like receptor 4. Furthermore, the DNA-binding activity of these proteins was confirmed by surface plasmon resonance assay. We demonstrated that pneumococcal DnaK, EF-Tu, and GAPDH induced the production of proinflammatory cytokines in macrophages, and might cause host tissue damage and affect the development of pneumococcal diseases.
Subject(s)
Autolysis/metabolism , DNA-Binding Proteins/metabolism , Streptococcus pneumoniae/metabolism , Animals , Bacterial Proteins , Chromatography, Liquid/methods , Cytokines/metabolism , DNA-Binding Proteins/physiology , Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism , Humans , Macrophages/metabolism , Macrophages, Peritoneal/metabolism , Male , Mice , Mice, Inbred BALB C , Molecular Chaperones/metabolism , Peptide Elongation Factor Tu/metabolism , Pneumococcal Infections/genetics , Streptococcus pneumoniae/genetics , THP-1 Cells , Tandem Mass Spectrometry/methods , Toll-Like Receptor 4/immunology , Toll-Like Receptor 4/metabolismABSTRACT
Streptococcus pyogenes is a bacterium that causes systemic diseases such as pharyngitis and toxic shock syndrome. S. pyogenes produces molecules that inhibit the function of the human immune system, thus allowing growth and spread of the pathogen in tissues. It is known that S. pyogenes CAMP factor induces vacuolation in macrophages; however, the mechanism remains unclear. In the current study, the mechanism by which CAMP factor induces vacuolation in macrophages was investigated. CAMP factor was found to induce calcium ion uptake in murine macrophage RAW264.7 cells. In addition, EDTA inhibited calcium ion uptake and vacuolation in the cells. The L-type voltage-dependent calcium ion channel blockers nifedipine and verapamil reduced vacuolation. Furthermore, the phosphoinositide 3-kinase inhibitors LY294002 and wortmannin also inhibited the vacuolation induced by CAMP factor. Fluorescent microscopy revealed that clathrin localized to the vacuoles. These results suggest that the vacuolation is related to calcium ion uptake by RAW264.7 cells via L-type voltage-dependent calcium ion channels. Therefore, it was concluded that the vacuoles induced by S. pyogenes CAMP factor in macrophages are clathrin-dependent endosomes induced by activation of the phosphoinositide 3-kinase signaling pathway through calcium ion uptake.
Subject(s)
Bacterial Proteins/metabolism , Bacterial Proteins/pharmacology , Calcium/metabolism , Hemolysin Proteins/metabolism , Hemolysin Proteins/pharmacology , Streptococcus pyogenes/metabolism , Animals , Chromones/antagonists & inhibitors , Edetic Acid/antagonists & inhibitors , Macrophages/drug effects , Macrophages/immunology , Mice , Morpholines/antagonists & inhibitors , Nifedipine/pharmacology , Phosphatidylinositol 3-Kinases/drug effects , RAW 264.7 Cells/drug effects , Signal Transduction/drug effects , Streptococcus pyogenes/immunology , Vacuoles/drug effects , Vacuoles/metabolism , Verapamil/pharmacologyABSTRACT
Vizantin is an insoluble adjuvant that activates macrophages and lymphocytes. Recently, 2,2',3,3',4,4'-hexasulfated-vizantin (sulfated vizantin), which enables solubilization of vizantin, was developed by the present team. Sulfated vizantin was found to enhance bactericidal activity against multi-drug resistant Pseudomonas aeruginosa in RAW264.7 cells. In addition, spread of P. aeruginosa was inhibited in RAW264.7 cells treated with sulfated vizantin. When only sulfated vizantin and P. aeruginosa were incubated, sulfated vizantin did not affect growth of P. aeruginosa. Formation of DNA-based extracellular traps (ETs), a novel defense mechanism in several types of innate immune cells, helps to eliminate pathogens. In the present study, ET-forming macrophages constituted the majority of immune cells. Sulfated vizantin induced ET formation in RAW264.7 cells, whereas a Ca-chelating reagent, EDTA, and T-type calcium channel blocker, tetrandrine, inhibited ET formation and attenuated inhibition of spread of P. aeruginosa in sulfated vizantin-treated cells. Thus, sulfated vizantin induces ET formation in phagocytic cells in a Ca-dependent manner, thus preventing spread of P. aeruginosa. Hence, sulfated vizantin may be useful in the management of infectious diseases.
Subject(s)
Extracellular Traps/drug effects , Glycolipids/pharmacology , Macrophages/drug effects , Macrophages/immunology , Trehalose/analogs & derivatives , Animals , Anti-Bacterial Agents/pharmacology , Benzylisoquinolines/pharmacology , Calcium/metabolism , Dimethylformamide/pharmacology , Drug Resistance, Multiple, Bacterial/drug effects , Edetic Acid/pharmacology , Macrophages/physiology , Mice , Nifedipine/pharmacology , Phagocytosis/drug effects , Pseudomonas Infections/immunology , Pseudomonas Infections/prevention & control , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/growth & development , Pseudomonas aeruginosa/immunology , RAW 264.7 Cells/drug effects , Sulfates/chemistry , Trehalose/pharmacologyABSTRACT
BACKGROUND: Clostridium perfringens epsilon-toxin is responsible for fatal enterotoxemia in ungulates. The toxin forms a heptamer in the lipid rafts of Madin-Darby Canine Kidney (MDCK) cells, leading to cell death. Here, we showed that epsilon-toxin requires neutral sphingomyelinase (nSMase) activity during oligomerization. METHODS: We tested the role of nSMase in the oligomerization of epsilon-toxin using specific inhibitors, knockdown of nSMase, formation of ceramide, and localization of epsilon-toxin and ceramide by immunofluorescence staining. RESULTS: Epsilon-toxin induced the production of ceramide is a dose- and time-dependent manner in ACHN cells. GW4869, an inhibitor of nSMase, inhibited ceramide production induced by the toxin. GW4869 and knockdown of nSMase blocked toxin-induced cell death and oligomer formation of epsilon-toxin. Confocal microscopy images showed that the toxin induced ceramide clustering and colocalized with ceramide. CONCLUSIONS: These results demonstrated that oligomer formation of epsilon-toxin is facilitated by the production of ceramide through activation of nSMase caused by the toxin. GENERAL SIGNIFICANCE: Inhibitors of nSMase may confer protection against infection.
Subject(s)
Bacterial Toxins/chemistry , Ceramides/agonists , Fibroblasts/enzymology , Membrane Microdomains/drug effects , Sphingomyelin Phosphodiesterase/metabolism , Aniline Compounds/pharmacology , Animals , Bacterial Toxins/toxicity , Benzylidene Compounds/pharmacology , Cell Line , Ceramides/biosynthesis , Clostridium perfringens/chemistry , Dogs , Enzyme Activation/drug effects , Enzyme Assays , Enzyme Inhibitors/pharmacology , Fibroblasts/cytology , Fibroblasts/drug effects , Gene Expression , Humans , Madin Darby Canine Kidney Cells , Membrane Microdomains/chemistry , Protein Multimerization , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Sphingomyelin Phosphodiesterase/antagonists & inhibitors , Sphingomyelin Phosphodiesterase/geneticsABSTRACT
An ideal antibiofilm strategy is to control both in the quality and quantity of biofilm while maintaining the benefits derived from resident microflora. Vizantin, a recently developed immunostimulating compound, has also been found to have antibiofilm property. This study evaluated the influence on biofilm formation of Streptococcus mutans in the presence of sulfated vizantin and biofilm development following bacterial adhesion on a hydroxyapatite disc coated with sulfated vizantin. Supplementation with sulfated vizantin up to 50 µM did not affect either bacterial growth or biofilm formation, whereas 50 µM sulfated vizantin caused the biofilm to readily detach from the surface. Sulfated vizantin at the concentration of 50 µM upregulated the expression of the gtfB and gtfC genes, but downregulated the expression of the gtfD gene, suggesting altered architecture in the biofilm. Biofilm development on the surface coated with sulfated vizantin was inhibited depending on the concentration, suggesting prevention from bacterial adhesion. Among eight genes related to bacterial adherence in S. mutans, expression of gtfB and gtfC was significantly upregulated, whereas the expression of gtfD, GbpA and GbpC was downregulated according to the concentration of vizantin, especially with 50 µM vizantin by 0.8-, 0.4-, and 0.4-fold, respectively. These findings suggest that sulfated vizantin may cause structural degradation as a result of changing gene regulation related to bacterial adhesion and glucan production of S. mutans.
Subject(s)
Bacterial Adhesion/drug effects , Biofilms/drug effects , Glycolipids/pharmacology , Streptococcus mutans/drug effects , Trehalose/analogs & derivatives , Gene Expression Regulation, Bacterial/drug effects , Glycolipids/chemistry , Streptococcus mutans/growth & development , Streptococcus mutans/physiology , Sulfates/chemistry , Trehalose/chemistry , Trehalose/pharmacologyABSTRACT
Dental caries affects people of all ages and is a worldwide health concern. Streptococcus mutans is a major cariogenic bacterium because of its ability to form biofilm and induce an acidic environment. In this study, the antibacterial activities of magnolol and honokiol, the main constituents of the bark of magnolia plants, toward planktonic cell and biofilm of S. mutans were examined and compared with those of chlorhexidine. The minimal inhibitory concentrations of magnolol, honokiol and chlorhexidine for S. mutans were 10, 10 and 0.25 µg/mL, respectively. In addition, each agent showed bactericidal activity against S. mutans planktonic cells and inhibited biofilm formation in a dose- and time-dependent manner. Magnolol (50 µg/mL) had greater bactericidal activity against S. mutans biofilm than honokiol (50 µg/mL) and chlorhexidine (500 µg/mL) at 5 min after exposure, while all showed scant activity against biofilm at 30 s. Furthermore; chlorhexidine (0.5-500 µg/mL) exhibited high cellular toxicity for the gingival epithelial cell line Ca9-22 at 1 hr, whereas magnolol (50 µg/mL) and honokiol (50 µg/mL) did not. Thus; it was found that magnolol has antimicrobial activities against planktonic and biofilm cells of S. mutans. Magnolol may be a candidate for prevention and management of dental caries.
Subject(s)
Anti-Bacterial Agents/pharmacology , Biofilms/drug effects , Biphenyl Compounds/pharmacology , Lignans/pharmacology , Magnolia/chemistry , Streptococcus mutans/drug effects , Cell Line , Dose-Response Relationship, Drug , Gingiva , Humans , Microbial Sensitivity Tests , Microscopy, Fluorescence , Plant Bark/chemistry , Plant Extracts/pharmacology , Streptococcus mutans/growth & developmentABSTRACT
Vizantin has immunostimulating properties and anticancer activity. In this study, we investigated the molecular mechanism of immune activation by vizantin. THP-1 cells treated with small interfering RNA for TLR-4 abolished vizantin-induced macrophage activation processes such as chemokine release. In addition, compared with wild-type mice, the release of MIP-1ß induced by vizantin in vivo was significantly decreased in TLR-4 knockout mice, but not in TLR-2 knockout mice. Vizantin induced the release of IL-8 when HEK293T cells were transiently cotransfected with TLR-4 and MD-2, but not when they were transfected with TLR-4 or MD-2 alone or with TLR-2 or TLR-2/MD-2. A dipyrromethene boron difluoride-conjugated vizantin colocalized with TLR-4/MD-2, but not with TLR-4 or MD-2 alone. A pull-down assay with vizantin-coated magnetic beads showed that vizantin bound to TLR-4/MD-2 in extracts from HEK293T cells expressing both TLR-4 and MD-2. Furthermore, vizantin blocked the LPS-induced release of TNF-α and IL-1ß and inhibited death in mice. We also performed in silico docking simulation analysis of vizantin and MD-2 based on the structure of MD-2 complexed with the LPS antagonist E5564; the results suggested that vizantin could bind to the active pocket of MD-2. Our observations show that vizantin specifically binds to the TLR-4/MD-2 complex and that the vizantin receptor is identical to the LPS receptor. We conclude that vizantin could be an effective adjuvant and a therapeutic agent in the treatment of infectious diseases and the endotoxin shock caused by LPS.
Subject(s)
Endotoxins/immunology , Glycolipids/pharmacology , Immunity/drug effects , Lymphocyte Antigen 96/metabolism , Trehalose/analogs & derivatives , Animals , Chemokine CCL4/biosynthesis , Cytokines/biosynthesis , Gene Expression , Glycolipids/metabolism , HEK293 Cells , Humans , Immunity/genetics , Inflammation Mediators/metabolism , Lipopolysaccharides/immunology , Lipopolysaccharides/pharmacology , Lymphocyte Antigen 96/chemistry , Lymphocyte Antigen 96/genetics , Macrophages/chemistry , Macrophages/drug effects , Macrophages/immunology , Macrophages/metabolism , Mice , Mice, Knockout , Models, Molecular , Protein Binding , Protein Conformation , Protein Transport , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism , Trehalose/metabolism , Trehalose/pharmacologyABSTRACT
Clostridium perfringens iota-toxin (Ia) mono-ADP ribosylates Arg177 of actin, leading to cytoskeletal disorganization and cell death. To fully understand the reaction mechanism of arginine-specific mono-ADP ribosyl transferase, the structure of the toxin-substrate protein complex must be characterized. Recently, we solved the crystal structure of Ia in complex with actin and the nonhydrolyzable NAD(+) analog ßTAD (thiazole-4-carboxamide adenine dinucleotide); however, the structures of the NAD(+)-bound form (NAD(+)-Ia-actin) and the ADP ribosylated form [Ia-ADP ribosylated (ADPR)-actin] remain unclear. Accidentally, we found that ethylene glycol as cryo-protectant inhibits ADP ribosylation and crystallized the NAD(+)-Ia-actin complex. Here we report high-resolution structures of NAD(+)-Ia-actin and Ia-ADPR-actin obtained by soaking apo-Ia-actin crystal with NAD(+) under different conditions. The structures of NAD(+)-Ia-actin and Ia-ADPR-actin represent the pre- and postreaction states, respectively. By assigning the ßTAD-Ia-actin structure to the transition state, the strain-alleviation model of ADP ribosylation, which we proposed previously, is experimentally confirmed and improved. Moreover, this reaction mechanism appears to be applicable not only to Ia but also to other ADP ribosyltransferases.
Subject(s)
ADP Ribose Transferases/chemistry , Actins/chemistry , Bacterial Toxins/chemistry , Clostridium perfringens/enzymology , NAD/chemistry , Protein Processing, Post-Translational , ADP Ribose Transferases/metabolism , Actins/metabolism , Bacterial Toxins/metabolism , NAD/analogs & derivatives , NAD/metabolism , Protein Structure, Quaternary , Protein Structure, TertiaryABSTRACT
Lipopolysaccharide (LPS) antagonists have attracted considerable interest as promising candidates for the treatment of severe sepsis triggered by Gram-negative bacteria. In this article, we describe the development of a novel LPS antagonist based on chemical hybridization of vizantin and the hydrophobic molecular unit of LPS (lipid A). Vizantin, 6,6'-bis-O-(3-nonyldodecanoyl)-α,α'-trehalose, was designed as an immunostimulator from a structure-activity relationship (SAR) study with trehalose 6,6'-dicorynomycolate (TDCM). Our recent study indicated that vizantin displays adjuvant activity by specifically binding to the Toll-like receptor 4 (TLR4)/MD2 protein complex. Because lipid A unit (or LPS) is also known to trigger an inflammatory response via the same TLR4/MD2 complex as vizantin, we designed a hybrid compound of vizantin and lipid A with the aim of developing a novel biofunctional glycolipid. Focusing on the antagonism to Escherichia coli LPS in an in vitro model with human macrophages (THP-1 cells), we identified a potent LPS antagonist among the synthesized hybrid compounds. The novel LPS antagonist effectively inhibited LPS-induced release of tumor necrosis factor-alpha (TNF-α) in a dose-dependent manner with an IC50 value of 3.8 nM, making it a candidate for the treatment drug of Gram-negative sepsis and/or septic shock.
Subject(s)
Glycolipids/pharmacology , Lipid A/pharmacology , Lipopolysaccharides/antagonists & inhibitors , Trehalose/analogs & derivatives , Glycolipids/chemistry , Humans , Lymphocyte Antigen 96/metabolism , Macrophages/metabolism , Structure-Activity Relationship , Toll-Like Receptor 4/metabolism , Trehalose/chemistry , Trehalose/pharmacologyABSTRACT
BACKGROUND: Most recent studies of Clostridium perfringens plasmids have focused on toxin-encoding or antibiotic resistance plasmids. To cause intestinal disease, a toxigenic strain must grow in the intestines to levels allowing for sufficient toxin production and this in vivo growth often involves overcoming the normal intestinal microbial population. For this purpose, bacteriocin production might be important. RESULTS: In this study, as the first step in the genetic analysis of a co-existing plasmid with an enterotoxin gene (cpe)-encoding plasmid, the bacteriocin gene-encoding plasmid, pBCNF5603, was completely sequenced. This plasmid has some homology with two previously sequenced C. perfringens plasmids, namely, pCP13 carrying a cpb2 gene and pIP404 carrying a bcn gene. Using recombinant plasmids, the rep gene homologous to the PCP63 gene on pCP13 appeared to be functional. Comparative genomics indicated that the identified rep gene homologs were found on two additional toxin plasmids, pCP-OS1 and pCP-TS1. While functional analysis using recombinant plasmids indicated that pBCNF5603 and pCP13 are likely to be incompatible, the plasmid replication and partitioning region of pBCNF5603 alone was insufficient for stable maintenance of this plasmid. CONCLUSIONS: These findings suggest that pBCNF5603 evolved from recombination events between C. perfringens plasmids and inter-species mobile genetic element(s). In addition, the bcn-encoding plasmid, pBCNF5603, is likely to be included in the Inc family, which includes pCP13 and two variant iota-encoding plasmids. Furthermore, the bcn gene on pBCNF5603 could contribute to gastrointestinal disease induced by enterotoxigenic C. perfringens.
Subject(s)
Bacteriocin Plasmids/genetics , Clostridium perfringens/genetics , DNA Replication , Enterotoxins/genetics , Enterotoxins/metabolism , Molecular Sequence Data , Sequence Analysis, DNA , Sequence Homology, Nucleic AcidABSTRACT
The methanol extract of the leaves of Illicium lanceolatum, indigenous to Fujian Province, People's Republic of China, was found to exhibit antimicrobial activity against the periodontal pathogen Porphyromonas gingivalis, and a bioassay-guided fractionation led to the isolation of two new compounds, 1 and 2, along with two known santalane-type sesquiterpenoids, 3 and 4. The structures of lanceolactone A (1) and lanceolactone B (2) were elucidated by analyzing their 2D NMR spectroscopic data. Compounds 1 and 2 were assigned as new tetranorsesquiterpenoids with a spiroacetal ring and tricyclic structure, respectively. Compound 3 (α-santal-11-en-10-one) showed potent antimicrobial activity against the oral pathogen P. gingivalis.
Subject(s)
Anti-Bacterial Agents , Drugs, Chinese Herbal , Illicium/chemistry , Porphyromonas gingivalis/drug effects , Sesquiterpenes , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/classification , Anti-Bacterial Agents/isolation & purification , Anti-Bacterial Agents/pharmacology , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/classification , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/pharmacology , Molecular Structure , Nuclear Magnetic Resonance, Biomolecular , Plant Leaves/chemistry , Plant Stems/chemistry , Sesquiterpenes/chemistry , Sesquiterpenes/classification , Sesquiterpenes/isolation & purification , Sesquiterpenes/pharmacologyABSTRACT
CONTEXT: Bacterial sphingomyelinase (SMase) is thought to play a crucial role in bacterial evasion of the immune response during the early stages of infections. OBJECTIVE: The objective of this study was to predict the chemical structure required for competitive SMase inhibition, then synthesize and test the effect of potential inhibitors on the hydrolysis of sphingomyelin (SM) and protection against infection by Bacillus cereus. MATERIALS AND METHODS: We synthesized 10 potential SMase inhibitors, derivatives of RY221B-a analogues, based on predictions from three-dimensional structural analysis. We then tested the effect of these compounds on the inhibition of SM hydrolysis and protection of mice inoculated with B. cereus. RESULTS: One compound, SMY-540, displayed a strong inhibitory effect (IC50 = 0.8 µM) upon SMase and prevented mortality in mice. CONCLUSION: SMY-540 is an effective inhibitor of Bc-SMase and has potential for use in the development of drugs to treat infectious diseases caused by bacteria that produce SMase.
Subject(s)
2,2'-Dipyridyl/analogs & derivatives , Bacillus cereus/drug effects , Bacterial Proteins/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Gram-Positive Bacterial Infections/drug therapy , Propanolamines/pharmacology , Sphingomyelin Phosphodiesterase/antagonists & inhibitors , 2,2'-Dipyridyl/chemical synthesis , 2,2'-Dipyridyl/chemistry , 2,2'-Dipyridyl/pharmacology , Animals , Bacillus cereus/enzymology , Bacillus cereus/pathogenicity , Bacillus subtilis/genetics , Bacillus subtilis/metabolism , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Gene Expression , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Hydrolysis , Inhibitory Concentration 50 , Male , Mice , Mice, Inbred BALB C , Mice, Inbred ICR , Molecular Docking Simulation , Propanolamines/chemical synthesis , Propanolamines/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sphingomyelin Phosphodiesterase/genetics , Sphingomyelin Phosphodiesterase/metabolism , Sphingomyelins/metabolism , Sphingosine/analogs & derivatives , Sphingosine/chemistry , Structure-Activity Relationship , Survival AnalysisABSTRACT
Immunotherapy is renowned for its capacity to elicit anti-infective and anti-cancer effects by harnessing immune responses to microbial components and bolstering innate healing mechanisms through a cascade of immunological reactions. Specifically, mammalian Toll-like receptors (TLRs) have been identified as key receptors responsible for detecting microbial components. The discovery of these mammalian Toll-like receptors has clarified antigen recognition by the innate immune system. It has furnished a molecular foundation for comprehending the interplay between innate immunity and its anti-tumor or anti-infective capabilities. Moreover, accumulating evidence highlights the crucial role of TLRs in maintaining tissue homeostasis. It has also become evident that TLR-expressing macrophages play a central role in immunity by participating in the clearance of foreign substances, tissue repair, and the establishment of new tissue. This macrophage network, centered on macrophages, significantly contributes to innate healing. This review will primarily delve into innate immunity, specifically focusing on substances targeting TLR4.